1	SENATE BILL NO. 122
2	AMENDMENT IN THE NATURE OF A SUBSTITUTE
3	(Proposed by the Senate Committee on General Laws and Technology
4	on)
5	(Patron Prior to SubstituteSenator VanValkenburg)
6	A BILL to require the Department of General Services to develop a strategy to increase efficiency in state
7	agency prescription drug purchasing and reduce spending on prescription drugs; report.
8	Be it enacted by the General Assembly of Virginia:
9	1. § 1. That the Department of General Services (the Department) shall develop a strategy to increase
10	efficiency in state agency prescription drug purchasing and reduce spending on prescription drugs. In
11	developing such strategy, the Department shall:
12	1. Identify every state agency that purchases prescription drugs to dispense or administer or that
13	provides pharmacy benefits for health plan enrollees and review the process by which such state agencies
14	currently negotiate and arrange for the purchase of prescription drugs or manage pharmacy benefits for
15	enrollees; and
16	2. Develop a list of prescription drugs currently purchased by state agencies that afford the greatest
17	opportunity for reducing prescription drug spending through multi-agency group procurement or other
18	cost control strategies and review the pharmacy benefit management contracts of state employee health
19	plans to assess strengths of different contracts and the feasibility of multi-agency pharmacy benefit
20	contracting and other pharmacy benefit management cost containment opportunities. In developing such
21	list, the Department shall:
22	a. Identify and prioritize consideration of the 25 most expensive prescription drugs purchased by
23	state agencies or covered by state agency health benefit programs in the previous calendar year; and
24	b. Identify and prioritize the 25 prescription drugs generating the highest total net spending among
25	state agencies in the previous calendar year.

§ 2. The Secretaries of Administration, Health and Human Resources, and Public Safety and
Homeland Security shall provide support to the Department in developing the strategy. The Department
shall provide an interim report on the findings of § 1 of this act to the Governor and the General Assembly
by November 1, 2024, and a final report on the findings with policy recommendations, if the opportunity
for cost savings is discovered, to the Governor and the General Assembly by November 1, 2025, which
shall include recommendations related to consolidating state agency prescription drug purchasing and
reimbursement programs, transitioning all pharmacy services to fee-for-service benefits, implementing
group purchasing arrangements or otherwise maximizing cost savings for state agencies based on drugs
identified in subdivision 2 of § 1 of this act, and identifying benefits to consumers and impacts on the
quality of health care received by state employees, Medicaid beneficiaries, and other patients who would
be affected by the development of a single purchasing entity.

#